Clinical Trial Management

Infectious Diseases & Vaccines

ICON CTMs are contributing to developing vaccines to prevent a multitude of diseases, including COVID-19, Ebola, epidemic flu (H1N1, H5N1), Respiratory Syncytial Virus (RSV), Zika, anthrax, plague, shigella, HSV, and many others. Our team supports vaccines for unique and relatively rare indications as well, including Dengue fever, Chikungunya, Yellow fever, and Mycobacterium tuberculosis.

Studies are conducted in healthy volunteers – from pediatric participants as young as 2 months to seniors well into their 90s – as well as patients suffering from acute infections anywhere in their body (blood, skin, intra-abdominal, etc.). Studies may focus on Gram-positive and/or Gram-negative bacteria, could demonstrate multiple resistance mechanisms to be overcome, and include a range of patients, from those able to attend outpatient visits to those in a critical care unit on mechanical ventilation or a subset of any of these. 

Addressing the variety of illnesses, affected body systems, and sample collection requirements of your studies will challenge you every day. Two key areas of important vaccines include those against malaria and tuberculosis – both of which are responsible for multiple deaths or chronic illness. 

The impact of these studies can often be immediate. Literature suggests that antibiotics are estimated to have increased average life expectancy by as much as 20 years in areas where they are readily available. And prophylactic vaccines are credited with preventing many millions of deaths per year across all age groups.